Unknown

Dataset Information

0

LunX-CAR T Cells as a Targeted Therapy for Non-Small Cell Lung Cancer.


ABSTRACT: Non-small cell lung cancer (NSCLC) carries a high mortality, and efficacious therapy is lacking. Therapy using chimeric antigen receptor (CAR) T cells has been used efficaciously against hematologic malignancies, but the curative effect against solid tumors is not satisfactory. A lack of antigen targets is one of the main reasons for this limited efficacy. Previously, we showed that lung-specific X (LUNX; also known as BPIFA1, PLUNC, and SPLUNC1) is overexpressed in lung cancer cells. Here, we constructed a CAR-T-cell-based strategy to target LunX (CARLunX T cells). CAR T cells were developed so that, upon specific recognition of LunX, they secreted cytokines and killed LunX-positive NSCLC cells. In vitro, CARLunX T cells displayed enhanced toxicity toward NSCLC lines and production of cytokines and showed specific LunX-dependent recognition of NSCLC cells. Adoptive transfer of CARLunX T cells induced regression of established metastatic lung cancer xenografts and prolonged survival. CARLunX T cells could infiltrate into the tumor. Also, we constructed a patient-derived xenograft model of lung cancer. After therapy with CARLunX T cells, tumor growth was suppressed, and survival was prolonged significantly. Together, our findings offer preclinical evidence of the immunotherapeutic targeting of LunX as a strategy to treat NSCLC.

SUBMITTER: Hu Z 

PROVIDER: S-EPMC7210386 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

LunX-CAR T Cells as a Targeted Therapy for Non-Small Cell Lung Cancer.

Hu Ziming Z   Zheng Xiaohu X   Jiao Defeng D   Zhou Yonggang Y   Sun Rui R   Wang Baolong B   Tian Zhigang Z   Wei Haiming H  

Molecular therapy oncolytics 20200421


Non-small cell lung cancer (NSCLC) carries a high mortality, and efficacious therapy is lacking. Therapy using chimeric antigen receptor (CAR) T cells has been used efficaciously against hematologic malignancies, but the curative effect against solid tumors is not satisfactory. A lack of antigen targets is one of the main reasons for this limited efficacy. Previously, we showed that lung-specific X (LUNX; also known as BPIFA1, PLUNC, and SPLUNC1) is overexpressed in lung cancer cells. Here, we c  ...[more]

Similar Datasets

| S-EPMC9161852 | biostudies-literature
| S-EPMC9816494 | biostudies-literature
| S-EPMC6781597 | biostudies-literature
| S-EPMC8586256 | biostudies-literature
| S-EPMC4940012 | biostudies-literature
| S-EPMC9994183 | biostudies-literature
| S-EPMC7426958 | biostudies-literature
| S-EPMC3991462 | biostudies-literature
| S-EPMC5723861 | biostudies-literature
| S-EPMC4727120 | biostudies-literature